» Articles » PMID: 30539038

Effectiveness of the Oral Human Attenuated Rotavirus Vaccine: A Systematic Review and Meta-analysis-2006-2016

Overview
Date 2018 Dec 13
PMID 30539038
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Gastroenteritis caused by rotavirus accounts for considerable morbidity in young children. We aimed to assess the vaccine effectiveness (VE) of the oral rotavirus vaccine , as measured by laboratory-confirmed rotavirus infection after referral to hospital and/or emergency departments in children aged <5 years with gastroenteritis.

Methods: We performed a systematic search for peer-reviewed studies conducted in real-life settings published between 2006 and 2016 and a meta-analysis to calculate the overall VE, which was further discriminated through stratified analyses.

Results: The overall VE estimate was 69% (95% confidence interval [CI], 62% to 75%); stratified analyses revealed a non-negligible impact of factors such as study design and socioeconomic status. Depending on the control group, VE ranged from 63% (95% CI, 52% to 72%) to 81% (95% CI, 69% to 88%) for unmatched and matched rotavirus test-negative controls. VE varied with socioeconomic status: 81% (95% CI, 74% to 86%) in high-income countries, 54% (95% CI, 39% to 65%) in upper-middle-income countries, and 63% (95% CI, 50% to 72%) in lower-middle-income countries. Age, rotavirus strain, and disease severity were also shown to impact VE, but to a lesser extent.

Conclusions: This meta-analysis of real-world studies showed that is effective in helping to prevent hospitalizations and/or emergency department visits due to rotavirus infection.

Citing Articles

Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors.

Pham S, Zhao B, Neetu N, Sankaran B, Patil K, Ramani S J Virol. 2025; 99(2):e0175724.

PMID: 39873493 PMC: 11852804. DOI: 10.1128/jvi.01757-24.


CONFORMATIONAL FLEXIBILITY IS A CRITICAL FACTOR IN DESIGNING BROAD-SPECTRUM HUMAN NOROVIRUS PROTEASE INHIBITORS.

Pham S, Zhao B, Neetu N, Sankaran B, Patil K, Ramani S bioRxiv. 2024; .

PMID: 39345439 PMC: 11430002. DOI: 10.1101/2024.09.16.613336.


Histo-Blood Group Antigen Null Phenotypes Associated With a Decreased Risk of Clinical Rotavirus Vaccine Failure Among Children <2 Years of Age Participating in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in Kenya, Mali, and the Gambia.

Schwartz L, Oshinsky J, Reymann M, Esona M, Bowen M, Hossain M Clin Infect Dis. 2023; 76(76 Suppl1):S153-S161.

PMID: 37074435 PMC: 10116560. DOI: 10.1093/cid/ciac910.


Impact of industry sponsorship on the quality of systematic reviews of vaccines: a cross-sectional analysis of studies published from 2016 to 2019.

Pieper D, Hellbrecht I, Zhao L, Baur C, Pick G, Schneider S Syst Rev. 2022; 11(1):174.

PMID: 35996186 PMC: 9395849. DOI: 10.1186/s13643-022-02051-x.


Differences in epidemiology of enteropathogens in children pre- and post-rotavirus vaccine introduction in Kilifi, coastal Kenya.

Agoti C, Curran M, Murunga N, Ngari M, Muthumbi E, Lambisia A Gut Pathog. 2022; 14(1):32.

PMID: 35915480 PMC: 9340678. DOI: 10.1186/s13099-022-00506-z.


References
1.
Correia J, Patel M, Nakagomi O, Montenegro F, Germano E, Correia N . Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis. 2010; 201(3):363-9. DOI: 10.1086/649843. View

2.
Patel M, Patzi M, Pastor D, Nina A, Roca Y, Alvarez L . Effectiveness of monovalent rotavirus vaccine in Bolivia: case-control study. BMJ. 2013; 346:f3726. PMC: 3687514. DOI: 10.1136/bmj.f3726. View

3.
Tate J, Burton A, Boschi-Pinto C, Parashar U . Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000-2013. Clin Infect Dis. 2016; 62 Suppl 2:S96-S105. DOI: 10.1093/cid/civ1013. View

4.
Muhsen K, Chodick G, Goren S, Shalev V, Cohen D . The uptake of rotavirus vaccine and its effectiveness in preventing acute gastroenteritis in the community. Vaccine. 2010; 29(1):91-4. DOI: 10.1016/j.vaccine.2010.10.010. View

5.
Gastanaduy P, Contreras-Roldan I, Bernart C, Lopez B, Benoit S, Xuya M . Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Guatemala. Clin Infect Dis. 2016; 62 Suppl 2:S121-6. DOI: 10.1093/cid/civ1208. View